Heart failure & cardiomyopathies
Transcatheter Edge-to-Edge Repair for SAM-Related Mitral Regurgitation in Patients With Hypertrophic Cardiomyopathy (HCM): The TRANSPARENT Registry
Authors' conclusion
M-TEER appears to be a feasible and safe therapeutic option for anatomically suitable patients with obstructive HCM, LV outflow tract obstruction, and SAM-related MR who are at high or prohibitive surgical risk.
Study context
- Population
- Symptomatic patients with obstructive HCM and moderate-to-severe or severe systolic anterior motion (SAM)-related mitral regurgitation (MR)
- Participants
- 35 patients
- Outcome
- MVARC technical, 30-day device and procedural success
Methodological detailsinternational, multicentre, 12 centres, Mitral Valve Academic Research Consortium (MVARC) definitions applied
- International
- Multicentre
- 12 centres
- MVARC definitions applied
Main finding
As reported in the abstract
MVARC technical success
94%
MVARC 30-day device success
91%
MVARC procedural success
88%
Observational data: associations, not effects.
Further findings
LVOT gradient, before vs after mitral edge-to-edge repair (M-TEER) · reduction persisted at median follow-up of 523 days
- LVOT gradient before (Q1-Q3: 35.5-92.0 mm Hg)
- 62.0 mm Hg
- LVOT gradient after (Q1-Q3: 12.0-22.0 mm Hg)
- 16.0 mm Hg
- Decrease
- P < 0.05
MR <2
- MR <2 achieved
- 97%
NYHA class I/II · last follow-up
- NYHA I/II before
- 31%
- NYHA I/II at last follow-up
- 88%
Composite of all-cause death, admission for acute decompensated HF, M-TEER re-do, surgical mitral valve replacement
- Composite outcome occurred, mainly driven by acute decompensated HF
- 26%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →